Abstract
Synopsis
The murine monoclonal antibody muromonab CD3 (0KT3) is directed against the CD3 antigen on peripheral human T cells and effectively blocks all T cell function.
Prophylaxis with muromonab CD3 (5mg intravenously once daily for 10 to 14 days) as induction therapy together with corticosteroids, azathioprine and delayed cyclosporin (sequential therapy) optimises early graft function by delaying the potentially nephrotoxic and hepatotoxic effects of cyclosporin until graft function is established.
Although clinical data are limited (by inconsistencies in trial design and trial size), prophylactic muromonab CD3-based sequential therapy is significantly more effective than standard triple therapy in the prophylaxis of allograft rejection in renal and hepatic, but not cardiac, transplant recipients. Benefits are particularly notable in patients with delayed graft function. No significant between-treatment differences in patient survival have been observed.
The overall efficacy of muromonab CD3- and polyclonal-based prophylactic regimens appears to be similar, although results vary between investigators and confirmation is needed. An anti-interleukin-2 monoclonal antibody-based prophylactic regimen improved graft and patient survival compared with muromonab CD3-based prophylaxis in hepatic transplant recipients.
Antimuromonab CD3 antibodies may develop; however, muromonab CD3 may be successfully reused in patients with low titres.
Preliminary pharmacoeconomic data suggest that mean drug costs are greater with quadruple immunosuppressive regimens containing muromonab CD3, antithymocyte globulin (ATG) or antilymphocyte globulin (ALG) than with triple therapy. Drug costs with prophylactic muromonab CD3-based regimens were similar or greater than those with polyclonal—based protocols.
The first doses of muromonab CD3 are associated with the ‘cytokine-release syndrome’. More severe first-dose events include aseptic meningitis, intragraft thromboses, seizures and potentially fatal pulmonary oedema. The incidence and/or severity of cytomegalovirus infection with prophylactic muromonab CD3-based immunosuppression is similar to or greater than that with triple therapy and ATG- or ALG-based regimens. However, the risk of infection and also the observed increase in lymphoproliferative disorders appears to be related to the degree of immunosuppression rather than to the drug itself.
Thus, sequential muromonab CD3-based therapy is more effective than standard triple therapy (in renal and hepatic transplant recipients) and appears to be similar to that of poly clonal-based regimens in the prophylaxis of transplant rejection. Although the routine use of prophylactic muromonab CD3 in low-risk patients with primary graft function does not appear to be justified, prophylactic muromonab CD3-based therapy has a role in patients at high risk of rejection.
Pharmacodynamic Properties
Muromonab CD3 (OKT3), a murine monoclonal antibody directed against the CD3 antigen (linked to the T cell antigen receptor; TCR) on mature peripheral human T cells, effectively blocks all T cell function. The mechanism of action includes antigenic modulation of the CD3/TCR complex with subsequent opsonisation and removal of circulating T cells; other mechanisms are proposed.
Cytokine release associated with an acute phase reaction occurs after the first doses of muromonab CD3. This is manifest as first-dose adverse events (see ‘Tolerability’ summary).
A biphasic reversible haemodynamic response and biphasic activation of coagulation and fibrinolysis, both of which coincide with cytokine release and/or complement activation, occur after initiation of muromonab CD3. Evidence suggests that intraoperative administration of the first muromonab CD3 dose is associated with fewer cardiovascular and pulmonary disturbances than administration in the immediate postoperative period.
High antimuromonab CD3 antibody titres (≥ 1:1000) were detected in 5.8 % of >12 000 serum samples from patients who received muromonab CD3 for the treatment or prevention of transplant rejection. IgG but not IgM antibodies are able to reduce the activity of muromonab CD3. Administration of concomitant immunosuppressants such as corticosteroids and azathioprine reduces the likelihood of antimuromonab CD3 antibody formation.
Pharmacokinetic Properties
Muromonab CD3 is a pure standardised product for which pharmacokinetic data are limited.
Plasma muromonab CD3 concentrations vary according to the muromonab CD3 ‘antibody status’, transplanted organ and age. Muromonab CD3 plasma concentrations were 996 μg/L after 1 hour and 104 μ/L at 24 hours in renal transplant recipients receiving 5mg once daily for 10 to 14 days. Mean trough steady-state serum concentrations range from 500 to 1000 μg/L after 2 to 4 days; approximately 1000 μg/L is required to block cytotoxic T cell function in vitro. Steady-state serum muromonab CD3 concentrations are achieved earlier with prophylactic administration than administration for the treatment of rejection. There is evidence of drug accumulation after repeated doses. Muromonab CD3 plasma elimination half-lives of approximately 18 hours (following administration for treatment of rejection) and 36 hours (prophylactic administration) have been reported.
Therapeutic Use
There are 2 main reasons for using muromonab CD3 as induction therapy in sequential immunosuppressive regimens (including azathioprine, methylprednisolone/prednisone and delayed cyclosporin): to optimise early graft function by delaying the administration of potentially nephrotoxic and hepatotoxic cyclosporin until graft function is established; and to reduce and delay the occurrence of rejection episodes.
Data from clinical trials of muromonab CD3-based prophylaxis are limited by trial size and inconsistencies in design. However, compared with triple therapy, prophylactic muromonab CD3-based sequential therapy was significantly more effective as assessed by severity and/or incidence of rejection episodes and time to first rejection episode in renal transplant recipients and by incidence and/or severity of early acute rejection episodes and time to first rejection in hepatic transplant recipients. Benefits appeared to be maintained for up to 3 years in renal transplant recipients and were particularly marked in patients with delayed graft function. In those with delayed renal graft function, overall graft survival was significantly greater with niuromonab CD3-based induction therapy than with triple therapy. Three-year graft survival in renal transplant recipients was signify icantly greater with sequential muromonab CD3-based therapy (delayed cyclosporin) than with cyclosporin-based therapy not containing muromonab CD3; in high-risk patients, sequential therapy was also associated with significantly greater 3-year graft survival rates than simultaneous muromonab CD3 and cyclosporin administration. Muromonab CD3-based prophylaxis appeared to be similar to triple therapy in terms of rejection incidence, time to first rejection episode and graft survival in cardiac transplant recipients. There were no significant between-treatment differences in patient survival for any type of transplant.
In renal transplant recipients, significantly more of those receiving muromonab CD3-based prophylaxis required postoperative dialysis than those receiving triple therapy; in hepatic transplant recipients, muromonab CD3 improved or maintained renal function in the early postoperative period.
Data on the relative effects of muromonab CD3-based and polyclonal-based prophylactic regimens are conflicting. In renal transplant recipients, some investigators show muromonab CD3- and antilymphocyte globulin (ALG)- or antithymocyte globulin (ATG)-based prophylaxis to be similar in terms of rejection incidence and/or time to first rejection, while others show ALG or ATG to be superior. The incidence of rejection episodes with muromonab CD3-based induction therapy in dual renal-pancreas transplant recipients is either similar to or lower than that with ALG- or ATG-based induction. Similarly, in cardiac transplant recipients, some studies show a longer time to first rejection episode and/or a lower incidence of rejection with muromonab CD3-based prophylaxis; others show no differences or a lower incidence of rejection or a longer time to first rejection episode with ATG-based therapy. Rejection episodes were fewer with ATG than with muromonab CD3 in the 1 available study in hepatic transplant recipients. Generally, no between-treatment differences were apparent in patient and graft survival or the incidence of delayed graft function. However, an anti-interleukin-2 monoclonal antibody-based prophylactic regimen improved graft and patient survival compared with muromonab CD3-based prophylaxis in hepatic transplant recipients.
Several noncomparative trials have shown early rejection in children and adolescents undergoing renal, hepatic or cardiac transplantation to be effectively reduced by prophylactic muromonab CD3 administered as part of a sequential immunosuppressive protocol. Although rejection incidence during the first 14 days was lower with muromonab CD3-based prophylaxis than with standard triple therapy in hepatic transplant recipients, no overall reduction was observed. Further comparative trials are needed to determine the relative benefits of prophylactic muromonab CD3 in this patient group.
Although muromonab CD3 reuse following prophylactic use is not recommended in patients with anti-idiotypic antibody titres ≥1: 1000, successful retreatment may occur in patients with lower titres.
Pharmacoeconomic Considerations
In theory, potential cost savings with prophylactic muromonab CD3 because of reduced rejection incidence compared with triple therapy may be offset by the increased incidence of infections and adverse events, but this has not been addressed in formal pharmacoeconomic assessments.
Preliminary data from cost-minimisation studies suggest that mean first-year drug costs are greater with quadruple immunosuppressive regimens containing muromonab CD3, ATG or ALG than with triple therapy, and hospital costs with prophylactic muromonab CD3-based regimens were similar to or greater than those with polyclonal-based protocols.
Tolerability
The first doses of muromonab CD3 are associated with flu-like ‘cytokine-release syndrome’ symptoms (e.g. fever, chills, gastrointestinal disturbance), which occur within 45 to 60 minutes and last for 2 to 48 hours. More severe but rare first-dose effects include aseptic meningitis, intragraft thromboses, seizures and potentially fatal pulmonary oedema. The incidence and severity of initial adverse events with muromonab CD3-based prophylaxis are similar to or greater than those associated with polyclonal antilymphocyte-based regimens.
Cytomegalovirus (CMV), herpes simplex virus and bacterial infections are the primary cause of morbidity and mortality in muromonab CD3 recipients. However, the risk of infection appears to be related to the degree of immunosuppression rather than to the drug itself. The risk of CMV infection is increased by high doses (total doses >75mg) and repeated exposure to muromonab CD3. The incidence and/or severity of CMV infection with prophylactic muromonab CD3-based immunosuppression is similar to or greater than that with triple therapy and ATG- or ALG-based regimens. The overall incidence of bacterial and fungal infections with these treatment options is largely similar.
Muromonab CD3-based immunosuppression has been associated with an increased risk of neoplasia, mainly lymphoproliferative disorders. However, this is most probably a direct result of the degree of immunosuppression; Epstein-Barr virus infection has also been implicated. The risk of lymphoproliferative disease may be increased by the use of high muromonab CD3 doses (total dose >75mg), long durations of administration, multiple courses and early retreatment. While some investigators report the incidence of neoplasia to be similar with muromonab CD3 and polyclonal preparations, others report a trend towards a greater incidence with muromonab CD3.
Other clinically significant pulmonary, cardiovascular or neurological events are uncommon.
Adverse events with muromonab CD3 may be prevented or minimised by the intraoperative administration of the first dose of muromonab CD3, pretreatment with a corticosteroid, administration of an antipyretic and antihistamine, prophylactic use of an antimicrobial(s) and correction of increased temperature and fluid overload before prophylaxis initiation.
Dosage and Administration
Induction therapy with muromonab CD3 together with azathioprine, methylpred-nisolone/prednisone and delayed cyclosporin therapy is the most accepted muromonab CD3-based regimen for allograft rejection prophylaxis.
Although the optimal dosage of muromonab CD3 has not been established, the currently recommended adult dosage is 5mg administered intravenously once daily for 10 to 14 days, irrespective of the organ transplanted. A dosage of 2.5 mg/day has usually been used in children although higher doses may be needed. The dosage should be adjusted according to the presence of clinical signs of rejection in addition to antimuromonab CD3 antibodies, plasma muromonab CD3 concentrations and CD3+ cell levels.
Patients should be closely monitored during administration of the first few doses. Intraoperative administration of the first dose and the use of preventative measures improve the tolerability of muromonab CD3.
Evidence suggests that procoagulant activity is increased with the concomitant administration of muromonab CD3 and high-dose corticosteroids, and indomethacin may increase the risk of encephalopathy and volatile anaesthetic agents or drugs that decrease cardiac contractility increase the risk of developing cardiovascular problems when administered with muromonab CD3.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Todd PA, Brogden RN. Muromonab CD3: a review of its pharmacology and therapeutic potential. Drugs 1989; 37: 871–99
Chatenoud L, Bach J-F. Selective immunosuppression with anti-T cell monoclonal antibodies. Clin Nephrol 1992; 38 Suppl. 1: 53–60
Roitt IM. OKT3: immunology, production, purification, and pharmacokinetics. Clin Transpl 1993 Aug; 7 (Pt 2): 367–73
Cosimi AB. Current and future application of monoclonal antibodies in clinical immunosuppressive protocols. Clin Transpl 1995 Jun; 9 (Pt 2): 219–26
Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17: 615–20
Gonçalves LF, Rauber ML, Manfro RC, et al. Fine needle aspiration biopsy in renal transplant patients on prophylactic OKT3 treatment. Transplant Proc 1992 Dec; 24: 3085–6
Ouwehand AJ, Baan CC, Groeneveld K, et al. Altered specificity of alloreactive cardiac graft-infiltrating cells by prophylactic treatment with OKT3 or horse antilymphocyte globulin. Transplantation 1993; 55: 154–8
Janssen O, Wesselborg S, Kabelitz D. Immunosuppression by OKT3 — induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 1992 Jan; 53: 233–4
Magnussen K, Klug B, Möller B. CD3 antigen modulation in T-lymphocytes during OKT3 treatment. Transplant Proc 1994 Jun; 26: 1731
Buysmann S, van Diepen FNJ, van Kooyk Y, et al. The influence of OKT3 on expression of lymphocyte adhesion molecules in vitro. Transplant Proc 1994 Dec; 26: 3249–50
Buysmann S, Bemelman FJ, Schellekens PT, et al. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87(1): 404–11
Wong JT, Eylath A, Ghobrial I, et al. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation 1990 Oct; 50: 683–9
Abramowicz D, Goldman M, De Pauw L, et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation — a single-center, prospective, randomized study. Transplantation 1992 Sep; 54: 433–7
Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–8
Ellenhorn JDI, Woodle ES, Ghobreal I, et al. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990 Oct; 50: 608–12
Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: association with T-cell subsets and cytokine release. Kidney Int 1991 Jan; 39: 141–8
Raasveld MHM, Bemelman FJ, Schellekens PThA, et al. Compliment activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993 May; 43: 1140–9
Chatenoud L. Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant Proc 1994 Dec; 26: 3191–3
Kreis H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transpl 1993 Aug; 7 (Pt 2): 431–46
Goumy L, Ferran C, Merite S, et al. In vivo anti-CD3-driven cell activation. Cellular source of induced tumour necrosis factor, interleukin-1β, and interleukin 6. Transplantation 1996; 61: 83–7
Bloemena E, ten Berge IJM, Surachno J, et al. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients. Transplantation 1990 Aug; 50: 330–1
Hoffman T, Tripathi AK, Lee YL, et al. Stimulation of human monocytes by anti-CD3 monoclonal antibody: induction of inflammatory mediator release via immobilization of Fc receptor by adsorbed immunoglobulin and T-lymphocytes. Inflammation 1992 Dec; 16: 571–85
Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc 1991; 23: 81–2
Vossen ACTM, Tibbe GJM, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25: 1492–6
Goldman M, Gérard C, Abramowicz D, et al. Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to posttransplant lymphoproliferative disorders. Clin Transpl 1992 Jun; 6: 265–8
Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertension 1993 Jul; 2: 670–8
Ferran C, Dy M, Merite S, et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990 Oct; 50: 642–8
Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990 Apr; 49: 697–702
Chatenoud L, Legendre C, Ferran C, et al. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome -dosage and kinetics prerequisites. Transplantation 1991 Feb; 51: 334–8
Schandené L, Gérard C, Crusiaux A, et al. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 55–6
Leimenstoll G, Zabel P, Schroeder P, et al. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplant Proc 1993 Feb; 25 (Pt 1): 561–3
Donckier V, Flament V, Gérard C, et al. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation 1994 May 27; 57: 1436–9
DeVault Jr GA, Kohan DE, Nelson EW, et al. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994 Feb 27; 57: 532–40
Alegre M-L, Gastaldello K, Abramowicz D, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991 Oct; 52: 674–9
Carey G, Lisi PJ, Schroeder TJ. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 1995; 60: 151–8
Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993 Apr; 25 Suppl. 1: 68–73
Norman DJ. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 1992; 12: 315–24
Kimball JA, Norman DJ, Shield CF, et al. OKT3 antibody response study: comparative testing of human antimouse antibody. Transplant Proc 1993 Apr; 25 Suppl. 1: 74–6
O’Connell JB, Bristow MR, Hammond EH, et al. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection. Transplant Proc 1991 Feb; 23: 1157–9
Schroeder TJ, Michael AT, First MR, et al. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther Drug Monit 1994 Aug; 16: 361–7
Taylor DO, Bristow MR, O’Connell JB, et al. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: decreased sensitization to OKT3. Transplantation 1994 Sep 27; 58: 645–9
Schroeder TJ, First MR, Mansour ME, et al. Antimurine antibody formation following OKT3 therapy. Transplantation 1990 Jan; 49: 48–51
Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993 Apr; 25 Suppl. 1: 89–92
Rohrer RJ, Jenkins RL, Khettry U, et al. Immunohistology of liver allografts in recipients managed with prophylactic OKT3. Transplant Proc 1989; 21: 2249–50
Kemnitz J, Cremer J, Schaefers HJ, et al. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3. J Heart Lung Transplant 1991 May-Jun; 10: 366–72
Kaufman C, Zeevi A, Zerbe T, et al. In vitro studies of endomyocardial biopsies from heart transplant recipients on RATG and OKT3 immunoprophylaxis protocols. Transplantation 1989; 48: 621–5
Fyfe AI, Harper CM. Anti-thymocyte globulin and OKT3 have opposite effects on adhesion of cardiac transplant recipient mononuclear cells to arterial endothelium [abstract]. Circulation 1993; 44: 1–41
Breisblatt WM, Schulman DS, Stein K, et al. Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence for reversible myocardial dysfunction. J Heart Lung Transplant 1991 May-Jun; 10: 359–65
Robinson ST, Barry JM, Norman DJ. The hemodynamic effects of intraoperative injection of muromonab CD3. Transplantation 1993 Aug; 56: 356–8
Stein KL, Ladowski J, Kormos R, et al. The cardiopulmonary response to OKT3 in orthotopic cardiac transplant recipients. Chest 1989 Apr; 95: 817–21
Beilman GJ, Shield III CF, Hughes JD, et al. The effects of intraoperative administration of OKT3 during renal transplantation. Transplantation 1993 Mar; 55: 490–3
Raasveld MHM, Hack CE, ten Berge IJM. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators. Thromb Haemost 1992 Sep 7; 68: 264–7
Abramowicz D, Pradier O, De Pauw L, et al. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 1994 Dec; 46: 1596–602
Pradier O, Marchant A, Abramowicz D, et al. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int 1992 Nov; 42: 1124–9
Goldman MH, McGrath G, Freeman M, et al. D-Dimer XDP correlates with fibrinolytic shutdown in renal transplant patients treated with anti-T-cell antibodies. Transplant Proc 1995 Feb; 27: 1094–6
Pradier O, Abramowicz D, Capel P, et al. Procoagulant properties of OKT3 at the monocyte level: inhibition by pentoxifylline. Transplant Proc 1993 Apr; 25 Suppl. 1: 39–40
Hesse CJ, Heyse P, Stolk BJM, et al. Differences in antibody formation to OKT3 between kidney and heart transplantation recipients. Transplant Proc 1989; 21: 979–80
Henell KR, Norman DJ. Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures. Transplant Proc 1993 Apr; 25 Suppl. 1: 83–5
Madden RL, Schroeder TJ, Alexander JW, et al. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response. Transplant Sci 1994 Sep; 4: 111–4
Goldstein G, Fuccello AJ, Norman DJ, et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42: 507–11
Schroeder TJ, First MR, Hurtubise PE, et al. Immunologic monitoring with Orthoclone OKT3 therapy. J Heart Transplant 1989 Sep-Oct; 8: 371–80
Norman DJ. The clinical role of OKT3. Cardiol Clin 1990 Feb; 8: 97–105
Hesse CJ, Heyse P, Stolk BJM, et al. Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis — induced anti-idiotypic and anti-isotypic anti-OKT3 antibodies do not prohibit depletion of peripheral T-cells due to second OKT3 treatment. Clin Transpl 1991 Dec; 5 (Part 1): 446–55
Goldstein G, Norman DJ, Henell KR, et al. Pharmacokinetic study of Orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 1988; 46: 587–9
Bock HA, Gallati H, Zürcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 1995 Mar 27; 59: 830–40
McDiarmid SV, Millis M, Terashita G, et al. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. Transplant Proc 1990 Aug; 22: 1774–6
Schroeder TJ, Ryckman FC, Hurtubise PE, et al. Immunological monitoring during and following OKT3 therapy in children. Clin Transpl 1991 Apr; 5: 191–6
Abramowicz D, Goldman M, Mat O, et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transpl Int 1994 Jul; 7: 258–63
McCarthy C, Light JA, Aquino A, et al. Correlation of CD3+ lymphocyte depletion with rejection and infection in renal transplants. Transplant Proc 1993 Aug; 25: 2477–8
Gebel H, Lebeck LL, Jensik SC, et al. Discordant expression of CD3 and T cell receptor antigens on lymphocytes from patients treated with OKT3. Transplant Proc 1989; 21: 1745–6
Shaefer MS, Stratta RJ, Pirruccello SJ, et al. Peripheral CD3 lymphocyte monitoring of liver transplant recipients being treated with OKT3 for rejection or induction immunosuppression [abstract]. Pharmacotherapy 1990; 10(3): 248
Broughan TA, Valenzuela R, Escorcia E, et al. Mouse antibodycoated lymphocytes during OKT3 therapy in liver transplantation. Clin Transpl 1994 Oct; 8: 488–91
Ohman M, Kotb M, Leathers LK, et al. Multiparameter monitoring of efficacy of OKT3-induced immune suppression in renal allograft recipients [abstract]. Hum Immunol 1993; 37 Suppl. 1: 95
Gebel HM, Lebeck LK, Jensik SC, et al. T cells from patients successfully treated with OKT3 do not react with the T-cell receptor antibody. Hum Immunol 1989 Oct; 26: 123–30
Hammond EA, Yowell RL, Greenwood J, et al. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. Transplantation 1993 May; 55: 1061–3
Moore CK, O’Connell JB, Renlund DG, et al. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. Transplant Proc 1991 Feb; 23: 1055–8
Ryckman FC, Schroeder TJ, Pedersen SH, et al. Use of monoclonal antibody immunosuppressive therapy in pediatric renal and liver transplantation. Clin Transplant 1991; 5: 186–90
Toyoda M, Galfayan K, Wachs K, et al. Immunologie monitoring of OKT3 induction therapy in cardiac allograft recipients. Clin Transplant 1995; 9: 472–80
Wechsler ME, Giardina E-GV, Sciacca RR, et al. Increased early mortality in women undergoing cardiac transplantation. Circulation 1995 Feb 15; 91: 1029–35
Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: a multivariate analysis. Transplantation 1995 Apr 15; 59: 962–8
Howard RJ, Pfaff WW, Brunson ME, et al. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Transplant Proc 1993 Feb; 25 (1 Pt 2): 884
Costanzo-Nordin MR, Fisher SG, O’Sullivan EJ, et al. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. J Heart Lung Transplant 1993 Sep-Oct; 12: 779–89
Kerman RH, Sullivan K, Tejani A. Impact of HLA matching, type of crossmatch and immunosuppressive therapy on primary pediatric cadaver renal allograft survival [abstract]. Hum Immunol 1994; 40 Suppl. 1: 17
Norman DJ, Kimball JA, Bennett WM, et al. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transpl Int 1994 Aug; 7: 356–61
Norman DJ, Barry JM, Bennett WM, et al. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transplant Proc 1991 Feb; 23: 1052–4
Alonso-Pulpón L, Serrano-Fiz S, Rubio JA, et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transplant 1995 Jan/Feb; 14 (1 Pt 1): 136–42
Welter HF, Illner W-D, Schleibner S, et al. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation. Transplant Proc 1990 Oct; 22: 2272
Hegewald MG, O’Connell JB, Renlund DG, et al. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1989 Jul-Aug; 8: 303–10
Kobashigawa JA, Stevenson LW, Brownfield E, et al. Does short-course induction with 0KT3 improve outcome after heart transplantation? A randomized trial. J Heart Lung Transplant 1993 Mar-Apr; 12: 205–8
Buysmann S, Hack CE, van Diepen FNJ, et al. Administration of OKT3 via continuous infusion attenuates first-dose side-effects. Kidney Int 1995; 48: 1368–9
Ortho Biotech Inc. Orthoclone OKT3 prescribing information. New Jersey, USA, 1995
Benvenisty AI, Cohen D, Stegall MD, et al. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990 Feb; 49: 321–7
Dafoe DC, Bromberg JS, Grossman RA, et al. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3. Transplantation 1991 Apr; 51: 762–8
Norman DJ, Kahana L, Stuart Jr FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993 Jan; 55: 44–50
Broyer M, Gagnadoux M-F, Guest G, et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Transplant Proc 1993 Feb; 25 (Pt 1): 570–1
Cole EH, Cattran DC, Farewell VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994 Jan; 57: 60–7
Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy–a prospective randomized trial of malg versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992 Jul; 54: 50–6
Hanto DW, Jendrisak MD, So SKS, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 1994 Feb 15; 57: 377–84
Steinmuller DR, Hayes JM, Novick AC, et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 1991 Jul; 52: 67–71
Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220–4
Vela C, Cristol JP, Chong G, et al. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients [abstract]. Nephrol Dial Transplant 1993; 8(9): 1052
Knechtle SJ, Pirsch JD, Groshek M, et al. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc 1991 Feb; 23: 1581–2
Lefrançois N, Raffaele P, Martinenghi S, et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transplant Proc 1990; 22: 632–3
Illner W-D, Theodorakis J, Abendroth D, et al. Quadruple-drug induction therapy in combined renal pancreatic transplantation–OKT3 versus ATG. Transplant Proc 1990 Aug; 22: 1586–7
Melzer JS, D’Alessandro AM, Kalayoglu M, et al. The use of OKT3 in combined pancreas-kidney allotransplantation. Transplant Proc 1990 Apr; 22: 634–5
Cosimi AB, Jenkins RL, Rohrer RJ, et al. Arandomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990 Jun; 125: 781–5
Farges O, Ericzon B-G, Bresson-Hadni S, et al. A randomized trial of OKT3-based versus cyclosporine-based immuno-prophylaxis after liver transplantation: long-term results of a European and Australian multicenter study. Transplantation 1994 Oct 27; 58: 891–8
McDiarmid SV, Millis MJ, Terasaki PI. OKT3 prophylaxis in liver transplantation. Dig Dis Sci 1991 Oct; 36: 1418–26
McDiarmid SV, Busuttil RW, Levy P, et al. The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation. Transplantation 1991 Jul; 52: 91–7
Mühlbacher F, Steininger R, Längle F, et al. OKT3 immunoprophylaxis in human liver transplantation. Transplant Proc 1989; 21: 2253–4
Pons JA, Bueno F, Parrilla P, et al. Cyclosporine vs OKT3 prophylaxis after orthotopic liver transplantation. Transplant Proc 1993 Apr; 25: 1949
Steininger R, Mühlbacher F, Hamilton G, et al. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 1991 Aug; 23: 2269–71
Reding R, Vraux H, de Goyet J de V, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993 Mar; 55: 534–41
Millis JM, McDiarmid S, Hiatt JR, et al. Randomized prospective trial of okt3 for early prophylaxis of rejection after liver transplantation. Transplantation 1989; 47: 82–8
Sasaki AW, Lee RG, Porayko MK, et al. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3. Transplantation 1993 Jan; 55: 216–9
Mor E, Skerrett D, Manzarbeitia C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995 Apr 15; 59: 986–90
Tokunaga Y, Tanaka K, Fujita S, et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. Transpl Int 1993 Nov; 6: 313–8
Fisher RA, Posner M, Shiffman ML, et al. Induction with OKT3 and prostaglandin E1 in liver transplantation. Transplant Sci 1994; 4 Suppl. 1: S1–8
Balk AHMM, Simoons ML, Jutte NHPM, et al. Sequential OKT3 and cyclosporine after heart transplantation. A randomized study with single and cyclic OKT3. Clin Transpl 1991 Aug; 5: 301–5
Barr ML, Sanchez JA, Seche LA, et al. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990 Nov; 82 Suppl. IV: IV–291–4
Stapleton DD, Ventura HO, Grundtner SE, et al. Induction immunosuppression with the monoclonal antibody OKT3 after cardiac transplantation. Am J Med Sci 1993 Jul; 306: 16–9
Costanzo-Nordin MR, O’Sullivan EJ, Johnson MR, et al. Prospective randomized trial of OKT3 versus horse antithymocyte globulin based immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1990 May-Jun; 9: 306–15
Griffith BP, Kormos RL, Armitage JM, et al. Comparative trial of immunoprophylaxis with RATG versus OKT3. J Heart Transplant 1990 May-Jun; 9: 301–5
Ippoliti G, Negri M, Abelli P, et al. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients. Transplant Proc 1991 Aug; 23: 2272–4
Kirklin JK, Bourge RC, White-Williams C, et al. Prophylactic therapy for rejection after cardiac transplantation–a comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg 1990 Apr; 99: 716–24
Ladowski JS, Dillon T, Schatzlein MH, et al. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. J Cardiovasc Surg 1993 Apr; 34: 135–40
Macdonald PS, Mundy J, Keogh AM, et al. A prospective randomized study of prophylactic OKT3 versus equine anti-thymocyte globulin after heart transplantation — increased morbidity with OKT3. Transplantation 1993 Jan; 55: 110–6
Menkis AH, Powell A-M, Novick RJ, et al. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. J Heart Lung Transplant 1992 May-Jun; 11: 569–76
Renlund DG, O’Connell JB, Gilbert EM, et al. A prospective comparison of murine monoclonal CD-3 OKT3 antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation decreased rejection and less corticosteroid use with OKT3. Transplantation 1989; 47: 599–605
Wollenek G, Laufer G, Laczkovics A, et al. Comparison of a monoclonal anti-T cell antibody vs ATG as prophylaxis after heart transplantation. Transplant Proc 1989; 21: 2499–501
van Gelder T, Mulder AH, Balk AHMM, et al. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. J Heart Lung Transplant 1995; 14: 346–50
Carrier M, Jenicek M, Pelletier LC. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis. Transplant Proc 1992 Dec; 24: 2586–91
Indudhara R, Khauli RB, Menon M. Simultaneous quadruple immunosuppression with cyclosporine induction therapy in high risk renal transplant recipients. J Urol 1994 Aug; 152 (Pt 1): 307–11
Schroeder TJ, First MR, Mansour ME, et al. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 1989 Nov; 14 Suppl. 2: 14–8
Abramowicz D, Norman DJ, Vereerstraeten P, et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. In press
Cardella CJ, Blake P, Cattran D, et al. Prophylactic OKT3 in renal retransplantation. Transplant Proc 1989 Apr; 21: 3373–4
Schroeder TJ, First MR, Gaber AO. Monitoring and management of immunosuppression in paediatric transplant patients. Clin Immunother 1995; 4(6): 425–44
Shaddy RE, Bullock EA, Morwessel NJ, et al. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart-transplant. J Heart Lung Transplant 1993 May-Jun; 12: 434–9
Brown JW, Turrentine MW, Kesler KA, et al. Triple-drug immunosuppression for heart transplantation in infants and children. J Heart Lung Transplant 1993 Nov-Dec; 12: S265–74
Conley SB, al-Uzri A, So S, et al. Prevention of rejection and graft loss with an aggressive quadruple immunosuppressive therapy regimen in children and adolescents. Transplantation 1994 Feb 27; 57: 540–4
Bartosh SM, Aronson AJ, Swanson-Pewitt EE, et al. OKT3 induction in pediatric renal transplantation. Pediatr Nephrol 1993 Feb; 7: 45–9
McDiarmid SV, Millis MJ, Terasaki P, et al. Induction of immunosuppression in pediatric orthoptopic liver transplantation. Clin Transpl 1991; 5: 174–80
Peters TG, Charlton RK, Jones KW, et al. Kidney transplantation in the older patient. J Fla Med Assoc 1994 Aug; 81: 535–8
Schroeder TJ, Rossi SJ, First MR. OKT3 monoclonal antibody therapy. International Consensus Conference on Immunosuppressive Drugs. 1995 5 May
Shield III CF. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival. Transplant Proc 1993 Apr; 25 Suppl. 1: 81–2
Hayes JM. The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. J Urol 1993 Mar; 149: 437–48
Niaudet P, Jean G, Broyer M, et al. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993 Jun; 7: 263–7
Mozes MF, Venkat KK, Kupin W, et al. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation? Transplant Proc 1993 Feb; 25 (Pt 1): 575–6
Rossi SJ, Schroeder TJ, Hariharan S. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993 Aug; 9: 104–31
Barclay PG, Allen RDM, Stewart JH, et al. Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc 1992 Feb; 24: 165–6
Mendez R, Aswad S, Khetan U, et al. Renal transplantation induction therapy — OKT3 vs MALG — outcome, cost [abstract]. Nephrol Dial Transplant 1995; 10(6): 1069
Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992 Sep 3; 340: 736
Peces R, Urra JM, Escalada P, et al. High-dose methylprednisolone inhibits the OKT3-induced cytokine-related syndrome. Nephron 1993 Jan; 63: 118
Costanzo-Nordin MR. Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction. Transplant Proc 1993 Apr; 25 Suppl. 1: 21–4
Bemelman FJ, Buysmann S, Surachno J, et al. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int 1994 Dec; 46: 1674–9
Jeyarajah DR, Thistlethwaite Jr JR. General aspects of cytokine-reiease syndrome: timing and incidence of symptoms. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 16–20
Abramowicz D, De Pauw L, Le Moine A, et al. Prevention of OKT3 nephrotoxicity after kidney transplantation. Kidney Int 1996; 49 Suppl. 53: S39–43
Shield III CF, Beilman G. Safety of OKT3 use in the operating room. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 43–4
Kupin W, Venkat KK, Ikemiyashiro D, et al. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients. Transplant Proc 1993 Feb; 25 (Pt 1): 572–4
Robinson ST. Administration of OKT3 in the operating room. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 41–2
Bolman III RM, Saffitz J. Early postoperative care of the cardiac transplantation patient: Routine considerations and immunosuppressive therapy. Prog Cardiovascular Dis 1990; 33: 137–48
Hayes MJ, Torzillo PJ, Sheil AGR, et al. Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transplant 1994 Dec; 8: 499–503
Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995 Jul 1; 123: 18–26
Rubin RH, Tolkoff-Rubin N. Minireview. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Ag Chemother 1993; 37: 619–24
Radhakrishnan J, Cohen D. Cytokine-release syndrome: General risk-factor modification — preparation of high-risk patients for use of OKT3. Transplant Proc 1993; 25 (2) Suppl. 1: 60–2
Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992 Mar 28; 339: 777–8
Woodle ES, Thistlethwaite Jr J, Emond JC, et al. OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation 1991 Jun; 51: 1207–12
Kehinde EO, Scriven SD, Feehally J, et al. Adverse effects of OKT3 therapy: increased risk with impaired renal function. Transplant Proc 1994 Aug; 26: 1945–7
Kehinde EO, Veitch PS, Scriven SD, et al. Complications of using OKT3 for induction of immunosuppression in recipients of kidneys from nonheart beating donors. Transplant Proc 1994 Dec; 26: 3123–5
Russ GR. Complications of immunosuppressive therapy in transplantation. 2: Specific immunosuppressive agents. Med J Aust 1992; 157: 264–7
Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991; 11(5): 119S–25S
Vasquez EM, Fabrega AJ, Pollak R. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 1995 Feb; 27: 873–4
Turner MC, Holman Jr JM. Late reactions during initial OKT-3 treatment. Clin Transpl 1993 Feb; 7 (Pt 1): 1–3
Kirklin JK, Naftel DC, Levine TB, et al. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. J Heart Lung Transplant 1994 May-Jun; 13: 394–404
Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992 Jan; 53: 68–72
Hooks MA, Perlino CA, Henderson JM, et al. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992 Apr; 19 Suppl. 33: 617–20
Tejada F, Gomez E, Aguado S, et al. OKT3 treatment induces higher prevalence and greater severity of cytomegalovirus disease in renal transplant [abstract]. Kidney Int 1994 Aug; 46: 582
Johnson MR, Mullen GM, O’Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 1994 Aug 1; 74: 261–6
Bailey TC, Powderly WG, Storch GA, et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993 Feb; 21: 196–201
Waser M, Maggiorini M, Liithy A, et al. Infectious complications in 100 consecutive heart transplant recipients. Eur J Clin Microbiol Infect Dis 1994 Jan; 13: 12–8
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990 Dec 20; 323: 1723–8
Burtin P, Boman F, Pinelli G, et al. Cancers following thoracic organ transplantation: a single center study. Transplant Proc 1995 Apr; 27: 1765
Stempfle HU, Mudra H, Angermann CE, et al. Rapid growth of cutaneous neuroendocrine (Merkel cell) carcinoma during, treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. J Heart Lung Transplant 1993 May-Jun; 12: 501–3
Penn I. Cancers complicating organ transplantation. N Engl J Med 1990 Dec 20; 323: 1767–9
Reyes CV, Jensen J, Chinoy M. Pulmonary lymphoma in cardiac transplant patients treated with OKT3 for rejection: diagnosis by fine-needle aspiration. Diagn Cytopathol 1995 Feb; 12: 32–6
Rinde-Hoffman D, Cintron GB, Ferguson JE, et al. Lymphoproliferative disorder early after cardiac transplantation [published erratum appears in Am J Cardiol 1992 Mar 15; 69 (8): 844]. Am J Cardiol 1991 Dec 15;68: 1724–5
Morgan G, Superina RA. Lymphoproliferative disease after pediatric liver transplantation. J Pediatr Surg 1994 Sep; 29: 1192–6
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993 Dec 18–25; 342: 1514–6
Emery RW, Lake KD. Post-transplantation lymphoproliferative disorder and OKT3 [letter]. N Engl J Med 1991 May 16; 324: 1437
Hardy MA, Benvenisty AI, Cohen D, et al. Incidence of malignancies in renal and cardiac transplant recipients in relation to treatment with biologic agents. Clin Transplantation 1992; 6 Special issue: 269–71
Haverty TP, Sanders M, Carey G. A 2-year follow-up of posttransplantation malignancy in renal allograft recipients receiving muromonab-CD3 for immunosuppressive induction therapy. Drug Invest 1992; 4(5): 403–8
Jones C, Bleau B, Buskard N, et al. Simultaneous development of diffuse immunoblastic lymphoma in recipients of renal transplants from a single cadaver donor: transmission of Epstein-Barr virus and triggering by OKT3. Am J Kidney Dis 1994 Jan; 23: 130–4
Cockfield SM, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft patients. Clinical experience and risk factor analysis in a single center. Transplantation 1993 Jul; 56: 88–96
Canfield CW, Hudnall SD, Colonna JO, et al. Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3-therapy. Clin Transpl 1992 Feb; 6: 1–9
Ratkovec RM, O’Connell JB, Bristow MR, et al. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. Clin Transpl 1992 Jun; 6: 260–4
Morrissey PE, Lorber KM, Marcarelli M, et al. Posttransplant Epstein-Barr virus infection is associated with elevated levels of CD19+ B lymphocytes. Transplantation 1995 Feb 27; 59: 637–40
Bernstein D, Baum D, Berry G, et al. Neoplastic disorders after pediatric heart transplantation. Circulation 1993 Nov; 88 (Pt 2): 230–7
Lee CW, Logan JL, Zukoski CF. Cardiovascular collapse following orthoclone OKT3 administration: a case report. Am J Kidney Dis 1991 Jan; 17: 73–5
Hall KA, Dole EJ, Hunter GC, et al. Hyperpyrexia-related ventricular tachycardia during OKT3 induction therapy. Transplantation 1992 Dec; 54: 1112–3
Coleman AE, Norman DJ. OKT3 encephalopathy. Ann Neurol 1990 Dec; 28: 837–8
Marks WH, Perkal M, Bia M. Aseptic encephalitis and blindness complicating OKT3 therapy. Clin Transpl 1991 Dec; 5 (Pt 1): 435–8
Shihab FS, Barry JM, Norman DJ. Encephalopathy following the use of OKT3 in renal allograft transplantation. Transplant Proc 1993 Apr; 25 Suppl. 1: 31–4
Alegre M-L, Depierreux M, Florquin S, et al. Nephrotoxicity of anti-CD3 monoclonal antibodies [in French]. Néphrologie 1991; 12: 42–5
Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993 Apr; 25 Suppl. 1: 27–30
First MR, Schroeder TJ, Hariharan S. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant Proc 1993 Apr; 25 Suppl. 1: 25–6
Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant 1994; 9(8): 1191–3
Doutrelepont J-M, Abramowicz D, Florquin S, et al. Early recurrence of hemolytic uremic syndrome in a renal transplant recipient during prophylactic OKT3 therapy. Transplantation 1992; 53: 1378–9
Bemelman FJ, Buysmann S, Yong SL, et al. Biphasic granulocytopenia after administration of the first dose of OKT3 [abstract]. Kidney Int 1995 Apr; 47: 1218
Burke III GW, Vercellotti GM, Simmons RL, et al. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting. Transplantation 1989 Sep; 48: 403–7
Vasquez EM, Pollak R. Effect of OKT3 therapy on cyclosporine blood levels [abstract]. Pharmacotherapy 1995 Jan-Feb; 15: 118–9
Chan GL, Weinstein SS, Wright CE, et al. Encephalopathy associated with OKT3 administration. Possible interaction with indomethacin. Transplantation 1991 Jul; 52: 148–50
Doutrelepont JM, Abramowicz D, Borre B, et al. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions. Transplant Proc 1993 Apr; 25 Suppl. 1: 45–6
Dantal J, Soulillou J-R. Use of monoclonal antibodies in human transplantation. Curr Opin Immunol 1991 Oct; 3: 740–7
Krensky AM, Clayberger C. Transplantation immunology. Pediatr Clin North Am 1994 Aug; 41: 819–39
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: D. Abramowicz, Department of Nephrology, Hôpital Erasme, Brussels, Belgium; P.N. Bennett, University of Bath, School of Postgraduate Medicine, Bath, England; H.A. Bock, Division of Nephrology, Kantonsspital, Basel, Switzerland; L. Chatenoud, Inserm U 25, Hôpital Necker, Paris, France; J.M. Grinyó, Institut Català de la Salut, Ciutat Sanitaria i Universitària de Bellvitge, Barcelona, Spain; K. Fukao, Department of Surgery, University of Tsukuba, Tsukuba City, Japan; G. Ippoliti, Clinica Medica II, IRCCS S Matteo, Pavia, Italy; L.J. Swinnen, Division of Hematology/Oncology, Stritch School of Medicine, Loyola University of Chicago, Illinois, USA; EM. Vasquez, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, USA
Rights and permissions
About this article
Cite this article
Wilde, M.I., Goa, K.L. Muromonab CD3. Drugs 51, 865–894 (1996). https://doi.org/10.2165/00003495-199651050-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199651050-00010